In Belgium, the use of transcatheter aortic valve implantation (TAVI) to treat severe aortic stenosis is currently limited to patients for whom surgical implantation represents an extreme or high risk. It is also subject to a volume cap. No cost-effectiveness analyses have been published in this setting for close to a decade, with previous analyses relying on early evidence from the study of balloon-expanding TAVI devices. Our objective was to generate an estimate of the potential cost-effectiveness of TAVI compared to surgical aortic valve replacement (SAVR) in high-risk patients, using contemporary data from studies of self-expanding TAVI devices.
